Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
BUSINESS
AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
AnGes said on July 26 that it will initiate an additional trial to gauge higher doses of its in-house developed DNA vaccine for COVID-19 to boost immunogenicity. The study is scheduled to start in early August, with the target enrollment…
To read the full story
Related Article
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
July 9, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
- Keio Univ. Spinout Weighs In on AnGes' COVID-19 Vaccine Initiatives
April 28, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- AnGes, Osaka Univ. to Pair Up to Develop DNA Vaccines for COVID-19
March 6, 2020
BUSINESS
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
- Tarlige Tops July Rep Promotion Ranking, Takes Back Crown from Mounjaro for GPs: Intage
October 3, 2023
- Kyorin to Cut Non-Sales Jobs through Voluntary Buyout
October 3, 2023
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…